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Striatal and cortical intranuclear inclusions and cytoplasmic aggregates of mutant huntingtin are prominent neuropathological hall-
marks of Huntington’s disease (HD). We demonstrated previously that transglutaminase 2 cross-links mutant huntingtin in cells in
culture and demonstrated the presence of transglutaminase-catalyzed cross-links in the HD cortex that colocalize with transglutaminase
2 and huntingtin. Because calmodulin regulates transglutaminase activity in erythrocytes, platelets, and the gizzard, we hypothesized that
calmodulin increases cross-linking of huntingtin in the HD brain. We found that calmodulin colocalizes at the confocal level with
transglutaminase 2 and with huntingtin in HD intranuclear inclusions. Calmodulin coimmunoprecipitates with transglutaminase 2 and
huntingtin in cells transfected with myc-tagged N-terminal huntingtin fragments containing 148 polyglutamine repeats (htt-N63-148Q-
myc) and transglutaminase 2 but not in cells transfected with myc-tagged N-terminal huntingtin fragments containing 18 polyglutamine
repeats. Our previous studies demonstrated that transfection with both htt-N63-148Q-myc and transglutaminase 2 resulted in cross-
linking of mutant huntingtin protein fragments and the formation of insoluble high-molecular-weight aggregates of huntingtin protein
fragments. Transfection with transglutaminase 2 and htt-N63-148Q-myc followed by treatment of cells with N-(6-aminohexyl)-1-
naphthalenesulfonamide, a calmodulin inhibitor, resulted in a decrease in cross-linked huntingtin. Inhibiting the interaction of calmod-
ulin with transglutaminase and huntingtin protein could decrease cross-linking and diminish huntingtin aggregate formation in the HD
brain.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurode-
generative disorder caused by an unstable CAG triplet repeat
expansion in the open reading frame of the first exon encoding a
polyglutamine stretch in the N terminus of the huntingtin pro-
tein. Neuropathological hallmarks of HD include perinuclear cy-
toplasmic aggregates and intranuclear inclusions of mutant hun-
tingtin (Davies et al., 1997; DiFiglia et al., 1997; Becher et al.,
1998; Gourfinkel-An et al., 1998; Ross et al., 1998; Gutekunst et
al., 1999). A current hypothesis is that the calcium-dependent
enzyme transglutaminase cross-links huntingtin protein to form
aggregates and intranuclear inclusions.
Transglutaminases are a family of calcium-activated enzymes
that catalyze the covalent cross-linking of peptide-bound glu-
tamine residues of substrate proteins to the -amino-group of
lysine residues on substrate proteins (Hand et al., 1993; Lorand,
1996; Cooper et al., 1999). The resulting isodipeptide bonds can
occur between or within substrate proteins, leading to conforma-
tional changes, dimers, or multimeric complexes (Selkoe et al.,
1982; Hand et al., 1993; Lorand, 1996).
Huntingtin with 40 CAG repeats is an excellent substrate for
transglutaminase 2 in vitro and in cell culture (Cariello et al.,
1996; Gentile et al., 1998; Kahlem et al., 1998; Cooper et al., 1999;
Karpuj et al., 1999; Violante et al., 2001). An increase in transglu-
taminase enzymatic activity and transglutaminase 2 protein has
been demonstrated in HD cases compared with controls (Karpuj
et al., 1999; Lesort et al., 1999). Huntingtin and transglutaminase
2 and huntingtin and transglutaminase-catalyzed cross-links co-
localize in HD brain tissue, and transglutaminase 2 cross-links
huntingtin in cells in culture (Zainelli et al., 2003).
Calmodulin regulates transglutaminase in systems such as the
human erythrocyte cytoskeleton (Billett and Puszkin, 1991), hu-
man platelets, and the chicken gizzard (Plank et al., 1983). In
these systems, calmodulin increased transglutaminase activity.
Calmodulin is a 17 kDa protein that activates a host of enzymes
during calcium binding (Cheung, 1982). A membrane-associated
erythrocyte transglutaminase cross-links substrates at physiolog-
ical and lower than physiological calcium concentrations in the
presence of calmodulin (Billett and Puszkin, 1991). Total trans-
glutaminase activity is threefold higher in the presence of cal-
modulin in human platelets and the chicken gizzard (Puszkin
and Raghuraman, 1985). It has also been demonstrated that hun-
tingtin binds strongly to calmodulin–Sepharose in the presence
of calcium, indicating that it may interact with huntingtin in vivo
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as well (Bao et al., 1996). Mutant huntingtin protein may bind to
calmodulin and then activate transglutaminase by bringing the
proteins into close enough proximity to interact. Thus, calmod-
ulin may also act to regulate transglutaminase cross-linking ac-
tivity in HD.
We examined the colocalization of both huntingtin protein
and the transglutaminase-catalyzed isopeptide bonds with cal-
modulin in intranuclear inclusions in HD. Lastly, we examined
the association of transglutaminase 2 and huntingtin with cal-
modulin and the effects of a calmodulin inhibitor on
transglutaminase-induced cross-linking of huntingtin in cells in
culture.
Materials and Methods
Human brain tissue. Control brain tissue (free from neurologic disease)
was obtained from the Loyola University Brain Bank (Table 1). HD brain
tissue was obtained from the Harvard Brain Tissue Resource Center and
the Brain Bank at The Johns Hopkins University School of Medicine. The
institutional protocols for sampling, processing, and storing specimens
are similar enough to quantitatively compare samples from these insti-
tutions. Tissue is blocked, frozen in isopentane, cooled on dry ice or on
glass plates, and then stored at 80°C. Frozen postmortem human cor-
tical (Brodman’s areas 45, 46, or area 9) brain tissue was obtained from
Vonsattel’s (Vonsattel et al., 1983) grade-three HD subjects for immu-
nofluorescent labeling and immunoblot experiments. The following
samples were used for immunofluorescent labeling experiments: HD
subjects [n  4; mean age, 61.5  5.48 (SEM); mean postmortem interval
(PMI), 20.98  1.99 hr (SEM)] and age-matched control subjects [n  4;
mean age, 63.75  4.23 (SEM); PMI, 19.00  2.52 hr (SEM)]. A t test
showed no significant difference between the mean age ( p  0.76) and
PMI ( p  0.59) of control versus HD tissue used in the immunofluores-
cent labeling experiments.
Antibodies. The monoclonal antibody (mAb) 81D4 (mouse IgM) di-
rected against the transglutaminase-induced cross-links was used at a
1:300 dilution for immunofluorescence experiments (CovalAb, Lyon,
France). mAb2166 (mouse IgG) is a monoclonal antibody to the N ter-
minus of the huntingtin protein sequence from amino acid 181– 812
(outside of the polyglutamine domain) that was used at a dilution of
1:100 for immunofluorescence (Chemicon, Temecula, CA). This anti-
body was reported to recognize both the normal and mutant forms of
huntingtin on Western blots (Trottier et al., 1995; Kahlem et al., 1998)
and to recognize huntingtin in the perikarya of neurons as punctate
staining (Trottier et al., 1995). The antibody to transglutaminase 2, TG-
100 (mouse IgG), was used at a dilution of 1:100 for immunofluorescence
and immunoblots (NeoMarkers, Union City, CA). The monoclonal an-
tibody to calmodulin, Cam I, was used at a dilution of 1:5000 on immu-
noblots (Santa Cruz Biotechnology, Santa Cruz, CA). The monoclonal
antibody against calmodulin, Cam85 (Zymed, South San Francisco, CA),
was used for immunofluorescence experiments at a dilution of 1:100. The
mAb 81D1c2 (mouse IgG) directed against the transglutaminase-
induced cross-links was used at a 1:500 dilution for immunoblots (Co-
valAb). The anti-myc antibody conjugated to horseradish peroxidase
(HRP) was used at a dilution of 1:2500 on immunoblots (Invitrogen,
Carlsbad, CA). An antibody to actin was used at a dilution of 1:1000 for
immunoblots (Sigma, St. Louis, MO).
Double-label immunofluorescence microscopy. Sections of fresh frozen
postmortem human brain tissue (16 m thick) from each Huntington’s
disease case and control cases were mounted on glass slides. The sections
were then fixed in 70% ethanol–0.9% NaCl. After blocking nonspecific
binding with 5% normal goat serum (NGS), sections were incubated
overnight in antibody directed to calmodulin, Cam85. Next, sections
were washed and incubated in goat anti-mouse (IgG fragment crystaliz-
able constant region chain specific, 1:100) conjugated to fluorescein iso-
thiocyanate (FITC) (Jackson ImmunoResearch, West Grove, PA). Tissue
sections were again incubated in 5% NGS to block nonspecific binding,
incubated overnight in the second primary antibody 81D4, and then
incubated in goat anti-mouse IgM antibody (-chain specific, which
recognizes 81D4 IgM, 1:100) conjugated to Rhodamine Red-X.
Another group of tissue sections was labeled with the primary anti-
body, Cam85, incubated with rabbit anti-mouse fab fragment to convert
recognition of the primary antibodies from IgG to a rabbit species, and
then incubated with goat anti-rabbit (1:100) conjugated to FITC (Jack-
son ImmunoResearch). This was done to prevent labeling of the two IgG
subclass primary antibodies (mAb2166 and TG-100) with the same sec-
ondary antibody. Sections were then incubated overnight in the second
primary antibody, mAb2166 (directed against the N terminus of the
huntingtin protein), or TG-100 (directed against transglutaminase 2).
Sections were washed and incubated in goat anti-mouse conjugated to
Rhodamine Red-X at a dilution of 1:00 (Jackson ImmunoResearch).
The tissue sections were incubated in 1% Sudan Black B for 10 min to
reduce the autofluorescence caused by lipofuscin (Schnell et al., 1999).
Next, coverslips were mounted on tissue sections with media containing
4,6-diamidino-2-phenylindole (DAPI), a dye that specifically labels
DNA and allows for the visualization of nuclei. As a control for nonspe-
cific labeling with secondary antibody, omission of primary antibodies
was also performed on a slide from each case (see Fig. 1 A,B). A pread-
sorption control was also performed for the 81D4 antibody to determine
its specificity. The specificity of the cross-link antibody, 81D4, was also
demonstrated in previous studies (El Alaoui et al., 1992; Norlund et al.,
1999). For example, in vitro incubation of tau protein with transglutami-
nase produced cross-linked tau that could be immunoprecipitated using
81D4 (Norlund et al., 1999).
Fluorescence and confocal microscopy. Tissue sections were examined
using a U-MCB fluorescence microscope (Olympus Optical, Tokyo, Ja-
pan) as well as an LSM 510 Axiovert laser scanning confocal microscope
(Zeiss, Thornwood, NY) to determine colocalization of antibody label-
ing. We examined the following combinations of antibodies: (1) cross-
link epitopes (labeled with Rhodamine Red-X) and calmodulin epitopes
(labeled with FITC), (2) transglutaminase 2 epitopes (labeled with Rho-
damine Red-X) and calmodulin epitopes (labeled with FITC), and (3)
cross-link epitopes (labeled with Rhodamine Red-X) and calmodulin
epitopes (labeled with FITC). Nuclei were visualized using DAPI under
ultraviolet illumination.
The Axiovert laser scanning confocal microscope (Zeiss) has a two-
track system in which the lasers are never on at the same time, thus
eliminating interference of one filter set with another and eliminating
bleed-through fluorescence. For each capture, the microscope imaging
system generated a three-channel (RGB), 512  512 pixel composite
image. The three channels of each image correspond to FITC or Rhoda-
mine Red-X and an overlaid colocalized image. Specifically, nuclei that
contained fluorescent labeling were analyzed for colocalization at the
confocal level within a 0.8-m-thick slice. Four control and four HD
cases were examined, and confocal images were obtained. One hundred
calmodulin-positive nuclei (25 nuclei from each of four HD cases) were
examined in each set of slides to determine the number that also con-
tained the huntingtin epitope, the transglutaminase 2 epitope, and the
cross-link epitope.
Cell culture system. Human embryonic kidney 293T (HEK 293T) cells
were grown in the presence of 5% CO2 and in OptiMEM reduced-serum
medium with HEPES buffer, L-glutamine, and sodium bicarbonate (In-
vitrogen). Nonessential amino acids, antimycotic and antibiotic agents,
and 10% FBS were also added to the medium. Cells were grown to 40 –
Table 1. HD and control brain tissue used in immunofluorescence experiments
Age (years) Gender Postmortem interval (hours)
HD cases
1 71 Male 20.5
2 46 Female 18.8
3 67 Female 23.6
4 62 Female 21.0
Control cases
1 53 Male 20.0
2 62 Male 12.0
3 67 Male 20.0
4 73 Male 24.0
Zainelli et al. • Calmodulin Regulates Cross-Linking Huntingtin J. Neurosci., February 25, 2004 • 24(8):1954 –1961 • 1955
50% confluence on 100 mm 2 culture dishes and transfected using Lipo-
fectamine Plus (Invitrogen). Transfection of the following constructs was
performed in various combinations: pcDNA3.1 as a vector control, myc-
tagged N-terminal huntingtin fragments containing 18 polyglutamine
repeats (htt-N63-18Q-myc) and myc-tagged N-terminal huntingtin
fragments containing 148 polyglutamine repeats (htt-N63-148Q) in
pcDNA3.1, and transglutaminase 2 in pcDNA3.1. Twenty-four hours
after transfection, cells were treated with various concentrations of N-(6-
aminohexyl)-1-naphthalenesulfonamide (w5-hydrochloride; Tocris
Cookson, Ballwin, MO) in some experiments. Forty-eight hours after
transfection, cells were harvested and resuspended in aggregate lysis
buffer containing 50 mM Tris-HCl, pH 8.8, 100 mM NaCl, 5 mM MgCl2,
0.05% NP-40, and 1 mM EDTA (Hazeki et al., 2000). The cell lysates were
then either run directly on Western blots, or a low-solubility fraction was
prepared. The low-solubility fraction was prepared by centrifugation of
the lysate at 12,000  g for 5 min and removal of the supernatant. The
pellet was then resuspended in 95% formic acid and incubated for 40 min
at 37°C in a shaking water bath, and then the formic acid was removed
under a vacuum (Hazeki et al., 2000). The pellets were then resuspended
in sample loading buffer and run on gels or resuspended in immunoaf-
finity purification buffer for additional analysis.
Immunoaffinity purification. Immunoaffinity purification of proteins
containing transglutaminase-induced -(-glutamyl) lysine cross-links
from 200 g of low-solubility protein lysate (1 g/l) was performed
using Sepharose beads prebound to the 81D4 antibody using a protocol
developed by CovalAb and as described previously (Norlund et al., 1999).
Immunoprecipitation with calmodulin–Sepharose. The low-solubility
fractions from lysates from the transfection of htt-N63-148Q-myc, htt-
N63-18Q-myc, transglutaminase 2, and vector combinations were im-
munoprecipitated with immobilized bovine brain calmodulin (Calbio-
chem, La Jolla, CA). A modification of the procedure was followed. First,
the immobilized calmodulin was washed with buffer containing (in M)
0.1 calcium phosphate, 0.1 magnesium chloride, and 0.1 Tris-HCl, pH
7.5. Samples were incubated with immobilized calmodulin for 1.5 hr
with gentle shaking. Next, immobilized calmodulin was washed for 5 min
and centrifuged for 5 min for a total of four washes. Elution of proteins
that bound to calmodulin was performed by addition of elution buffer
containing (in M) 0.1 EGTA and 0.1 Tris-HCl, pH 7.4.
Immunoblots. Cell lysates and immunoaffinity-purified protein lysates
were analyzed using 3– 8% Tris–acetate denaturing gels for cell-culture
experiments (Novex system; Invitrogen) and then electrophoretically
transferred to nitrocellulose membranes. Nonspecific antibody labeling
was blocked with a solution of 5% nonfat dry milk in Tris-buffered saline
with 0.05% Triton X-100. After overnight incubation in primary anti-
body, blots incubated with TG-100, calmodulin, or actin antibodies were
either incubated in goat anti-mouse secondary antibody conjugated to
horseradish peroxidase (Cappel, Aurora, OH) or incubated with peroxi-
dase–antiperoxidase (Sigma). Autoradiograms were produced using the
ECL advanced chemiluminescence reagents. Blots incubated with the
-myc antibody conjugated to HRP were washed and then directly incu-
bated with ECL reagents (Amersham Biosciences, Buckinghamshire,
UK). Experiments were performed in triplicate with similar results.
Treatment with w5-hydrochloride. To determine whether calmodulin
regulates transglutaminase cross-linking activity and aggregate forma-
tion, we used the calmodulin inhibitor w5-hydrochloride (Tocris Cook-
son) at concentrations ranging from 50 to 1000 M in the cell culture
system. We determined whether the calmodulin antagonist affected ag-
gregate formation in cells by immunoaffinity purification of cross-
linked, insoluble proteins and Western blotting. We then used antibodies
against huntingtin (anti-myc antibody) to recognize cross-linked hun-
tingtin proteins on immunoblots. Transglutaminase and huntingtin ex-
pression were verified using the transglutaminase antibody and -myc
antibody (recognizes huntingtin) on immunoblots.
Digital fluorescence imaging of intracellular calcium levels. HEK 293T
cells were grown on 25 mm glass coverslips that were coated with colla-
gen. Cells were loaded with 1 M of the calcium-sensitive indicator fura-2
AM (Molecular Probes, Eugene, OR) (Takahashi et al., 1999) in HBSS for
15 min at 37°C. The coverslips were rinsed twice with HBSS and then fit
into a holder. The holder was filled to 1 ml with warm HBSS and
mounted onto the stage of the Axiovert 135 inverted microscope (Zeiss).
At least 15 regions of interest (containing multiple cells each) were mon-
itored for calcium measurements using a 40 oil objective on the micro-
scope. Digital images were visualized on a computer monitor and cap-
tured using a two-camera system. The excitation emission from a xenon
lamp alternates between 340 nm (calcium bound) and 380 nm (calcium
free), and emission was measured at 520 nm. After at least 180 sec of
baseline calcium fluorescence intensity, w5-hydrochloride was added in
successive aliquots of molar concentrations of 50 and 100 M without
washing out drug added previously. These additions resulted in a 1 mM
final concentration of w5-hydrochloride added with no alteration of
intracellular calcium levels. As a positive control, ionomycin was added
at a concentration of 2.5 M. Fluorescent signals were measured for a
change in the fura-2 ratio. Fluorescent signals were obtained, saved, and
analyzed using the Attofluor RatioVision System (Zeiss).
Results
Calmodulin colocalizes with proteins in intranuclear
inclusions in the HD brain
Twenty-five nuclei from each of four different HD cases were
examined for the colocalization of calmodulin and either trans-
glutaminase 2, huntingtin, or the transglutaminase-induced
-(-glutamyl) lysine cross-link. There was a very high degree of
colocalization of calmodulin protein with transglutaminase 2,
cross-links, and huntingtin proteins. A total of 98% of
huntingtin-positive nuclei colabel with the calmodulin antibody,
whereas 100% of calmodulin-positive nuclei also label with the
huntingtin antibody (Fig. 1D). A total of 99% of calmodulin-
positive nuclei colocalize with transglutaminase 2 epitopes,
whereas 100% of transglutaminase 2-positive nuclei colocalize
with calmodulin epitopes (Fig. 1E). Finally, 100% of cross-link-
positive nuclei colocalize with calmodulin epitopes, whereas
100% of calmodulin-positive nuclei colocalize with cross-link
epitopes (Fig. 1C).
Immunoprecipitation of calmodulin and transglutaminase 2
HEK 293T cells were transfected with the following: (1) hunting-
tin containing a normal-length glutamine domain (i.e., htt-N63-
18Q-myc) and vector, (2) transglutaminase 2 and htt-N63-18Q-
myc, (3) huntingtin with a polyglutamine domain expansion
(i.e., htt-N63-148Q-myc) and vector, or (4) transglutaminase 2
and htt-N63-148Q-myc. The insoluble fractions from these ly-
sates were immunoprecipitated using anti-calmodulin–Sepha-
rose and run directly on immunoblots. Calmodulin was only found
in the insoluble fraction from cells transfected with transglutaminase
2 and htt-N63-148Q-myc; calmodulin was not in the insoluble frac-
tion from cells transfected with transglutaminase 2 and htt-N63-
18Q-myc, cells transfected with htt-N63-148Q-myc and vector, or
cells transfected with htt-N63-18Q-myc and vector (Fig. 2A). Trans-
glutaminase 2 coimmunoprecipitates with calmodulin from cells
cotransfected with transglutaminase 2 and htt-N63-148Q-myc (Fig.
2B). Transglutaminase 2 did not coimmunoprecipitate from cells
cotransfected with htt-N63-18Q-myc and vector, cells transfected
with htt-N63-18Q-myc and transglutaminase 2, or cells cotrans-
fected with htt-N63-148Q-myc and vector (Fig. 2B). Two bands are
present in the immunoblots prepared with the huntingtin antibody
(Fig. 2C). One band is in the lane corresponding to cotransfection of
vector and htt-N63-148Q-myc, and the other band is in the lane
corresponding to cotransfection of transglutaminase 2 and htt-N63-
148Q-myc (Fig. 2C). Calmodulin protein was loaded directly on the
gel for use as a positive control for the immunoblots (Fig. 2A).
Treatment with w5-hydrochloride
Twenty-four hours after transient cotransfection of transglu-
taminase 2 and htt-N63-148Q-myc, cells were treated with 0, 50,
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100, or 500 M w5-hydrochloride, a cal-
modulin inhibitor. Transfection of both
transglutaminase 2 and htt-N63-148Q-
myc resulted in cross-linking of the hun-
tingtin protein, as did htt-N63-148Q-myc
alone (Fig. 3A, first and second lanes, re-
spectively). As a result of treatment with
the calmodulin inhibitor, there were not
observable levels of cross-linked hunting-
tin proteins detectable on the immuno-
blots with any of the doses of w5-
hydrochloride administered (Fig. 3A).
To determine whether w5-hydrochloride
regulates transglutaminase cross-linking di-
rectly and not by altering intracellular cal-
cium levels, we measured intracellular levels
of calcium in untransfected cells using the
fluorescent ratiometric calcium indicator
fura-2 AM. (Molecular Probes) (Takahashi
et al., 1999). We found that doses of w5-
hydrochloride (50 and 100 M) that prevent
cross-linking of huntingtin did not signifi-
cantly alter the intracellular calcium levels
(Fig. 3D). Doses up to 1000 M did not alter
intracellular calcium levels (data not
shown).
Discussion
The goal of this study was to determine
whether calmodulin is involved in the
pathogenesis of HD. We found that cal-
modulin is present in intranuclear inclu-
sions in HD cortical tissue. We also ob-
served a high degree of colocalization of
calmodulin with huntingtin, transglu-
taminase 2, and the transglutaminase-
induced cross-links within nuclei in the
HD cortex. These findings suggest that cal-
modulin associates with and may be a
component of intranuclear inclusions.
Previous studies demonstrated that trans-
glutaminase selectively cross-links patholog-
ical-length huntingtin (40Q) over hun-
tingtin with normal-length glutamine
domains (Cariello et al., 1996; Gentile et al.,
1998; Kahlem et al., 1998; Karpuj et al.,
1999). It was also demonstrated previously
that huntingtin proteins that have expanded
glutamine domains bind to calmodulin–
Sepharose with greater affinity than hun-
tingtin with normal-length glutamine do-
mains (Bao et al., 1996).
Our studies demonstrate that transglu-
taminase and calmodulin and polyglu-
tamine-expanded huntingtin and calmodu-
lin coimmunoprecipitate from the insoluble
fraction of cells that were cotransfected with
htt-N63-148Q-myc and transglutaminase 2
but do not coimmunoprecipitate in cells that
were transfected with huntingtin containing
a normal-length glutamine domain (htt-
N63-18Q-myc). The anti-calmodulin anti-
body labeled the calmodulin protein in the
Figure 1. Nuclei that contained intranuclear inclusions were first localized by fluorescence microscopy using DAPI. Colocaliza-
tion of each epitope was examined by fluorescence microscopy, and control slides were produced in which both primary antibod-
ies were omitted (each separately as well as both combined) from the assay to ensure that the secondary antibodies did not
cross-react in a nonspecific manner. For example, colocalization of calmodulin and huntingtin was examined in A. In the same
experiment, FITC fluorescent labeling was examined after omission of the calmodulin primary (1°) antibody and Rhodamine Red-X
(RhRed) fluorescent labeling was examined after omission of the huntingtin primary antibody ( B). Confocal images of intranu-
clear inclusions ( C–E) depict labeling of each antibody and colocalization of epitopes (yellow color). A, B, 1000 final magnifi-
cation; C–E, 4000 magnification.
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control lane and calmodulin in the insoluble fraction from cotrans-
fection of polyglutamine-expanded huntingtin and transglutami-
nase 2 but not from cotransfection of polyglutamine-expanded hun-
tingtin and vector (Fig. 2A). The myc-positive band representing
cotransfection of polyglutamine-expanded huntingtin and transglu-
taminase 2 was consistently darker than the band representing co-
transfection of polyglutamine-expanded huntingtin and vector (Fig.
2C). The low levels of endogenous transglutaminase 2 could play a
role in the weaker association of calmodulin and huntingtin in the
cells not transfected with transglutaminase 2. The observation of a
lighter band in the lane representing cotransfection of polyglu-
tamine-expanded huntingtin and vector compared with huntingtin
and transglutaminase 2 (Fig. 2C) suggests that there is less huntingtin
associated with calmodulin in the cells and could also explain why
there was no visible calmodulin immunoreactivity from the cotrans-
fection of polyglutamine-expanded huntingtin and vector com-
pared with cotransfection of polyglutamine-expanded huntingtin
and transglutaminase 2 (Fig. 2A).
The pathological length of huntingtin may be a trigger for trans-
glutaminase cross-linking activity in HD. Mutant huntingtin pro-
teins (with glutamine expansions) may bind both transglutaminase
2 and calmodulin in cells. Calmodulin– huntingtin–transglu-
taminase complexes may then activate transglutaminases that cross-
link huntingtin fragments together, forming stable insoluble aggre-
gates and inclusions. Calmodulin may be providing the calcium
needed for activation of transglutaminase. Because huntingtin and
calmodulin interact with high affinity, the calmodulin may then re-
main bound to huntingtin and become part of the insoluble aggre-
gates that are formed via transglutaminase cross-linking of hunting-
tin. Calmodulin does not appear to be cross-linked by
transglutaminase (data not shown) but is present in the insoluble
Figure 2. Insoluble fractions of proteins from lysates of cotransfections were solubilized
with formic acid. Samples were then immunoprecipitated (IP) with the anti-calmodulin anti-
body and examined on immunoblots (IBs). Antibodies to calmodulin ( A), transglutaminase 2
( B), and huntingtin (-myc) ( C) were used on the immunoblots. Calmodulin protein was also
directly loaded in the first lane of the gels as a positive control. TGase 2, Transglutaminase 2.
Figure 3. Cells transiently transfected with htt-N63-148Q-myc and transglutaminase 2
(TGase 2) or htt-N63-148Q-myc and vector were treated with increasing concentrations of the
calmodulin inhibitor w5-hydrochloride ( A). The insoluble fraction of lysates was solubilized
with formic acid, and cross-linked proteins were immunoprecipitated (IP) with the cross-link-
directed antibody 81D4. Samples were then run on Western blots and probed with anti-myc
antibody (which recognizes huntingtin fragments) ( A). HEK 293T cells were loaded with fura-2
AM, and a calcium baseline was obtained. The calmodulin inhibitor w5-hydrochloride was
added in increasing concentrations starting with 50 M ( B). The w5-hydrochloride was not
washed out before additional drug treatment and thus resulted in a final concentration of 300
M in this experiment. The w5-hydrochloride had no effect on intracellular calcium concentra-
tions. Each tracing represents the ratio of bound to unbound calcium in a single cell in this
representative experiment. The minor depressions in the tracings at the time of drug treatment
are an artifact resulting from the addition of a liquid and do not represent an actual calcium flux.
There was a robust increase in intracellular calcium levels during treatment with the calcium
ionophore ionomycin, which was used as a positive control ( B). IB, Immunoblot.
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fraction in cells transfected with htt-N63-148Q-myc and transglu-
taminase 2 and also is a component of intranuclear inclusions in the
HD brain.
All cell-culture experiments in this study used constructs en-
coding N-terminal fragments of huntingtin protein rather than
full-length huntingtin protein. N-terminal fragments of mutant
huntingtin protein exist in HD cases, and although controversial,
there is evidence suggesting that N-terminal fragments rather
than full-length huntingtin are present in the intranuclear inclu-
sions in HD (DiFiglia et al., 1997; Mende-Mueller et al., 2001;
Kegel et al., 2002). Transgenic mice expressing the N-terminal
fragments of mutant huntingtin protein develop pathological
changes more rapidly and develop a more severe neuropathol-
ogy, including more intranuclear inclusions (Li et al., 2000;
Meade et al., 2002; Menalled and Chesselet, 2002). However, the
relative significance of mouse models using truncated versus full-
length huntingtin constructs remains contentious. In cells in cul-
ture, truncated huntingtin protein increases aggregate formation
and susceptibility to cell death (Martindale et al., 1998).
The calmodulin inhibitor w5-hydrochloride prevents cross-
linking of huntingtin in cells that are cotransfected with htt-N63-
148Q-myc and transglutaminase 2. Intracellular calcium levels
were not altered by the calmodulin inhibitor at 50 –1000 M,
concentrations that prevent cross-linking of huntingtin by trans-
glutaminase 2. Therefore, the effect of the calmodulin inhibitor is
specific and is not merely a result of altered calcium levels in cells.
Additionally, dysregulation of calcium homeostasis (Tang et
al., 2003) may contribute to increases in calcium levels in the
neuronal nucleus and cytosol, resulting in inappropriate activa-
tion of transglutaminases that leads to intranuclear inclusion for-
mation (Cooper et al., 1999). Striatal and cortical regions may not
have sufficient calcium-buffering capacity, thereby resulting in
increased vulnerability of these neurons and their degeneration
(Sieradzan et al., 1999). For example, levels of PEP-19, a
calmodulin-binding protein, are decreased in HD and in Alzhei-
mer’s disease in selectively vulnerable brain regions (Utal et al.,
1998). This finding suggests that dysregulation of calcium– calm-
odulin homeostasis may play a role in the pathophysiology of
HD. It is possible that mutant huntingtin disrupts calmodulin-
mediated intracellular processes that involve PEP-19 (Utal et al.,
1998). Proteins that regulate calcium homeostasis such as PEP-
19, calmodulin, calbindin, and calretin bind intracellular calcium
and act as intracellular calcium buffers (Baimbridge et al., 1992).
These proteins may also be involved in abnormal transglutami-
nase activity.
Calmodulin plays a role in regulating cross-linking of proteins
in the human erythrocyte cytoskeleton (Billett and Puszkin,
1991), human platelets (Puszkin and Raghuraman, 1985), and
the chicken gizzard (Puszkin and Raghuraman, 1985), and may
regulate transglutaminase in neurodegenerative disease. Our
findings suggest that calmodulin regulates transglutaminase
cross-linking of the mutant huntingtin fragments. Additional
studies need to be done to confirm that calmodulin regulates the
activity of transglutaminases in HD. Inhibition of calmodulin is a
way of altering transglutaminase cross-linking of huntingtin in
cells in culture but may not be a feasible therapeutic strategy in
humans because of the host of other enzymes that calmodulin
regulates, such as phosphodiesterases, adenylate cyclases, phos-
phatases, protein kinases, and ATPases (Hazeki et al., 2002). An
important role of calmodulin is to activate nitric oxide synthases
(Daff, 2003) and calmodulin kinases (Deckel, 2001). In mice
transgenic for the HD mutation, there are increased levels of
calmodulin kinase IV and nitric oxide synthase (Deckel, 2001)
and decreased levels of calmodulin in late stages (Deckel et al.,
2002). Calmodulin may be sequestered in aggregates with hun-
tingtin protein in the HD transgenic mice, as seen in HD in this
current study. Inhibiting the sequestration of calmodulin in the
aggregates and the interaction of calmodulin with transglutami-
nase and huntingtin protein may allow calmodulin to function
normally and reduce aggregate formation and stability. Calmod-
ulin modulates calmodulin kinase IV that regulates transcription
factors that may contribute to neuronal dysfunction and cell
death in HD (Steffan et al., 2000; Jiang et al., 2003). Calmodulin
also modulates nitric oxide synthase, which normally is involved
in neurotransmission, cerebral blood flow, endocrine regulation,
and other normal processes but can have a neurotoxic, oxidative
stress effect under pathological conditions (Deckel et al., 2002;
Montgomery et al., 2003). Overall, modulation of calmodulin
may be a useful tool to determine the pathogenic mechanisms in
HD.
Transglutaminase-catalyzed cross-linking of huntingtin pro-
tein fragments is a plausible mechanism of formation of insoluble
aggregates of huntingtin protein and stabilization of the intranu-
clear inclusions found in postmortem HD tissue. Our laboratory
has demonstrated previously the colocalization of huntingtin,
transglutaminase 2, and the transglutaminase-catalyzed cross-
link in HD cortical intranuclear inclusions (Zainelli et al., 2003).
We also demonstrated that transglutaminase cross-links mutant
huntingtin proteins (with polyglutamine expansions) into insol-
uble aggregates in cells in culture. Evidence suggests that forma-
tion of intracellular aggregates and inclusions in other neurode-
generative diseases is also attributable to transglutaminase cross-
linking. For example, the neurofibrillary tangles in Alzheimer’s
disease (Norlund et al., 1999; Singer et al., 2002) and progressive
supranuclear palsy (Zemaitaitis et al., 2000) and Lewy bodies in
Parkinson’s disease (Junn et al., 2003) contain transglutaminase-
catalyzed cross-links. Transglutaminase-catalyzed cross-linking
may also be involved in inclusion formation in other triplet re-
peat disorders in addition to HD (Ross et al., 1998). To prevent
the seemingly detrimental activity of transglutaminase in HD and
other neurodegenerative diseases, agents that inhibit transglu-
taminase are currently under investigation (Dedeoglu et al., 2002;
Karpuj et al., 2002a,b). It has been demonstrated that the chem-
ical inhibitor cystamine decreases transglutaminase activity, de-
creases aggregate formation, increases viability of cells in culture,
and improves motor function in a mouse model of HD (Dedeo-
glu et al., 2002). In this study, we found that calmodulin is in-
volved in regulation of transglutaminase cross-linking of the
huntingtin protein, and that calmodulin may be a factor involved
in intranuclear inclusion formation in HD. These studies lay the
foundation for the understanding and development of novel ap-
proaches to regulate transglutaminase cross-linking and aggre-
gate formation to increase neuroprotection in HD.
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